Adam Durczyński
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adam Durczyński has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Hogendorf
Department of General and Transplant Surgery, Medical University of Lodz, Poland
48 shared publications Janusz Strzelczyk
Department of General Surgery and Transplantology, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Lodz, Poland
35 shared publications- Wojciech Ciesielski
Department of General Surgery and Transplantology, Norbert Barlicki Memorial Teaching Hospital No. 1, Medical University of Lodz, 90-153 Lodz, Poland
16 shared publications - Janusz Strzelczyk
Department of General and Transplant Surgery, Medical University of Lodz, Poland
13 shared publications - Janusz Strzelczyk
Department of General and Transplant Surgery, Medical University of Lodz, 90-419 Lodz, Poland
12 shared publications Anna Kumor
Klinika Pneumonologii i Alergologii, Uniwersytet Medyczny w Łodzi
10 shared publications
Latest Publications
- Open Access
Simple Algorithm for Blood Morphology Analysis (SAMBA): An Artificial Intelligence-Assisted Approach to Identify Peripheral Blood Phenotypes in a Cohort of Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
Introduction: Eosinophils have become important therapeutic targets in several allergic diseases. This study aimed to apply a similar approach—using peripheral blood findings to identify features of type 2 (T2) inflammation—to oncology. We used Simple Algorithm for Blood Morphology Analysis (SAMBA) to describe blood count profiles in a cohort of patients with PDAC independently of relative ratios and propose a potential classification. Materials and Methods: We included 153 treatment-naïve patients with PDAC confirmed by postoperative histopathology. Of these, n = 68 (44.4%) underwent curative surgery, whereas n = 85 (55.6%) received palliative treatment or underwent surgical biopsy only. SAMBA was applied using laboratory reference ranges and overall survival (OS; months) as the analytical context. Results: The subgroups defined according to laboratory reference ranges did not differ significantly in disease stage, grade, or resection status. Based on correlation analyses, Kaplan–Meier curves, and a classification and regression tree (CART) analysis of OS, we propose four blood count phenotypes: exhausted, lymphopenic, T2-low, and T2-high (median OS: 1.5 months, n = 22; 4.5 months, n = 12; 8.0 months, n = 25; and 10.0 months, n = 94, respectively). Conclusions: We propose the following preliminary interpretations of these phenotypes: exhausted, potentially associated with concomitant infection or marked inflammation; lymphopenic, characterized by a low lymphocyte count and potentially reduced antitumor immune activity; eosinopenic (T2-low), characterized by a relatively balanced inflammatory profile but limited T2-associated features; and eosinophilic (T2-high), characterized by no major abnormalities in the other blood count parameters and a more favorable prognosis. SAMBA is a transparent, readily interpretable algorithm that may help standardize and accelerate preliminary research in immuno-oncology.
Open AccessSimple Algorithm for Blood Morphology Analysis (SAMBA): An Artificial Intelligence-Assisted Approach to Identify Peripheral Blood Phenotypes in a Cohort of Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
Introduction: Eosinophils have become important therapeutic targets in several allergic diseases. This study aimed to apply a similar approach—using peripheral blood findings to identify features of type 2 (T2) inflammation—to oncology. We used Simple Algorithm for Blood Morphology Analysis (SAMBA) to describe blood count profiles in a cohort of patients with PDAC independently of relative ratios and propose a potential classification. Materials and Methods: We included 153 treatment-naïve patients with PDAC confirmed by postoperative histopathology. Of these, n = 68 (44.4%) underwent curative surgery, whereas n = 85 (55.6%) received palliative treatment or underwent surgical biopsy only. SAMBA was applied using laboratory reference ranges and overall survival (OS; months) as the analytical context. Results: The subgroups defined according to laboratory reference ranges did not differ significantly in disease stage, grade, or resection status. Based on correlation analyses, Kaplan–Meier curves, and a classification and regression tree (CART) analysis of OS, we propose four blood count phenotypes: exhausted, lymphopenic, T2-low, and T2-high (median OS: 1.5 months, n = 22; 4.5 months, n = 12; 8.0 months, n = 25; and 10.0 months, n = 94, respectively). Conclusions: We propose the following preliminary interpretations of these phenotypes: exhausted, potentially associated with concomitant infection or marked inflammation; lymphopenic, characterized by a low lymphocyte count and potentially reduced antitumor immune activity; eosinopenic (T2-low), characterized by a relatively balanced inflammatory profile but limited T2-associated features; and eosinophilic (T2-high), characterized by no major abnormalities in the other blood count parameters and a more favorable prognosis. SAMBA is a transparent, readily interpretable algorithm that may help standardize and accelerate preliminary research in immuno-oncology.
- Open Access
Perioperative Thyroid-Metabolic Changes in Pancreatic Ductal Adenocarcinoma According to Surgical Management
Background: Pancreatic ductal adenocarcinoma (PDAC) is associated not only with tumor progression but also with profound metabolic and nutritional disturbances. Thyroid hormone homeostasis may reflect this systemic response; however, perioperative data in PDAC remain limited. We aimed to assess perioperative changes in thyroid-related parameters in patients with PDAC undergoing different types of surgical management and to explore their associations with nutritional, metabolic, and tumor-burden variables. Methods: We performed a retrospective single-center study including 101 patients with PDAC. Thyroid-related and metabolic laboratory parameters were assessed before surgery and again 4–6 weeks later. The analyzed variables included thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), the FT3/FT4 ratio, albumin, total protein, glucose, insulin, HbA1c, lipid parameters, and CA 19-9. Patients were analyzed according to resectional versus non-resectional treatment and according to four procedure types. The primary endpoint was perioperative change in the FT3/FT4 ratio. Results: At baseline, resectional patients had significantly higher FT3 and FT3/FT4 ratio values and lower FT4 and CA 19-9 levels than non-resectional patients. In the whole cohort, FT3 and the FT3/FT4 ratio decreased significantly after treatment, whereas TSH increased, and FT4 remained unchanged. These endocrine changes occurred in parallel with significant declines in albumin, total protein, glucose, insulin, HbA1c, and HDL cholesterol, together with an increase in triglyceride levels. Baseline FT3 and FT3/FT4 ratios correlated positively with albumin and total protein and negatively with CA 19-9. Although perioperative changes did not differ significantly between resectional and non-resectional groups except for triglycerides, significant procedure-dependent differences were observed across the four surgical categories for FT3, FT4, TSH, and the FT3/FT4 ratio; glucose; insulin; and triglycerides. The prevalence of low-T3 syndrome increased from 11.1% preoperatively to 38.7% postoperatively. Conclusions: In PDAC, perioperative changes in thyroid hormone indices are pronounced and strongly depend on the type of surgical management. FT3 and the FT3/FT4 ratio appear to reflect systemic metabolic and nutritional adaptation as well as disease burden rather than acting as tumor-specific markers.
Open AccessPerioperative Thyroid-Metabolic Changes in Pancreatic Ductal Adenocarcinoma According to Surgical Management
Background: Pancreatic ductal adenocarcinoma (PDAC) is associated not only with tumor progression but also with profound metabolic and nutritional disturbances. Thyroid hormone homeostasis may reflect this systemic response; however, perioperative data in PDAC remain limited. We aimed to assess perioperative changes in thyroid-related parameters in patients with PDAC undergoing different types of surgical management and to explore their associations with nutritional, metabolic, and tumor-burden variables. Methods: We performed a retrospective single-center study including 101 patients with PDAC. Thyroid-related and metabolic laboratory parameters were assessed before surgery and again 4–6 weeks later. The analyzed variables included thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), the FT3/FT4 ratio, albumin, total protein, glucose, insulin, HbA1c, lipid parameters, and CA 19-9. Patients were analyzed according to resectional versus non-resectional treatment and according to four procedure types. The primary endpoint was perioperative change in the FT3/FT4 ratio. Results: At baseline, resectional patients had significantly higher FT3 and FT3/FT4 ratio values and lower FT4 and CA 19-9 levels than non-resectional patients. In the whole cohort, FT3 and the FT3/FT4 ratio decreased significantly after treatment, whereas TSH increased, and FT4 remained unchanged. These endocrine changes occurred in parallel with significant declines in albumin, total protein, glucose, insulin, HbA1c, and HDL cholesterol, together with an increase in triglyceride levels. Baseline FT3 and FT3/FT4 ratios correlated positively with albumin and total protein and negatively with CA 19-9. Although perioperative changes did not differ significantly between resectional and non-resectional groups except for triglycerides, significant procedure-dependent differences were observed across the four surgical categories for FT3, FT4, TSH, and the FT3/FT4 ratio; glucose; insulin; and triglycerides. The prevalence of low-T3 syndrome increased from 11.1% preoperatively to 38.7% postoperatively. Conclusions: In PDAC, perioperative changes in thyroid hormone indices are pronounced and strongly depend on the type of surgical management. FT3 and the FT3/FT4 ratio appear to reflect systemic metabolic and nutritional adaptation as well as disease burden rather than acting as tumor-specific markers.
- Open Access
Endoscopic Ultrasound-Guided Versus Percutaneous Transhepatic Biliary Drainage After Failed Endoscopic Retrograde Cholangiopancreatography in Malignant Biliary Obstruction: A Single-Center Retrospective Cohort
Background: After a failed endoscopic retrograde cholangiopancreatography (ERCP) for malignant biliary obstruction (MBO), second-line drainage is performed with endoscopic ultrasound-guided biliary drainage (EUS-BD) or percutaneous transhepatic biliary drainage (PTBD). We compared their effectiveness, safety, and short-term survival. Methods: We conducted a single-center retrospective cohort of 101 adults with MBO after they had experienced a failed ERCP (EUS-BD n = 37; PTBD n = 64). Allocation was non-randomized and driven by operational availability. Baseline laboratory tests (complete blood count, platelets, and C-reactive protein) and derived indices (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], lymphocyte-to-monocyte ratio [LMR], systemic immune-inflammation index [SII], systemic inflammation response index [SIRI], neutrophil-to-platelet score [NPS], and lymphocyte-to-CRP ratio [LCR]) were compared. Outcomes that were a technical success include: an early biochemical response (bilirubin reduction), complications (Clavien–Dindo), length of stay (LOS), and overall survival (OS). Between-group comparisons used the two-sided Mann–Whitney U test (continuous) and Fisher’s exact (binary) test. Survival was assessed by the Kaplan–Meier estimator using log-rank testing. To address later adoption of EUS-BD, we also estimated a restricted mean survival time of 180 days (RMST_0–180) with 95% confidence intervals (CIs). Results: Baseline inflammatory markers and composite indices were similar; baseline total bilirubin was higher in PTBD. The technical success was 100% in both groups. Early biochemical response was 86.5% after EUS-BD vs. 78.1% after PTBD (p = 0.43). Any complication occurred in 29.7% vs. 12.5% (p = 0.04); major complications (Clavien–Dindo ≥ III) occurred in 10.8% vs. 0% (p = 0.02), respectively; and the LOS did not differ (p = 0.21). OS favored EUS-BD (median 143 vs. 54 days and log-rank p = 0.012). RMST_0–180 was 111.1 days for EUS-BD vs. 71.4 days for PTBD (difference + 39.6 days; 95% CI 11.3–65.9). Conclusions: After a failed ERCP for MBO, EUS-BD and PTBD achieved universal technical success and similar early biochemical responses, but EUS-BD was associated with higher complication rates and a significantly longer six-month survival. These findings support the individualized selection balancing procedural risk with the anticipated survival benefit and highlight the need for prospective comparative studies.
Open AccessEndoscopic Ultrasound-Guided Versus Percutaneous Transhepatic Biliary Drainage After Failed Endoscopic Retrograde Cholangiopancreatography in Malignant Biliary Obstruction: A Single-Center Retrospective Cohort
Background: After a failed endoscopic retrograde cholangiopancreatography (ERCP) for malignant biliary obstruction (MBO), second-line drainage is performed with endoscopic ultrasound-guided biliary drainage (EUS-BD) or percutaneous transhepatic biliary drainage (PTBD). We compared their effectiveness, safety, and short-term survival. Methods: We conducted a single-center retrospective cohort of 101 adults with MBO after they had experienced a failed ERCP (EUS-BD n = 37; PTBD n = 64). Allocation was non-randomized and driven by operational availability. Baseline laboratory tests (complete blood count, platelets, and C-reactive protein) and derived indices (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], lymphocyte-to-monocyte ratio [LMR], systemic immune-inflammation index [SII], systemic inflammation response index [SIRI], neutrophil-to-platelet score [NPS], and lymphocyte-to-CRP ratio [LCR]) were compared. Outcomes that were a technical success include: an early biochemical response (bilirubin reduction), complications (Clavien–Dindo), length of stay (LOS), and overall survival (OS). Between-group comparisons used the two-sided Mann–Whitney U test (continuous) and Fisher’s exact (binary) test. Survival was assessed by the Kaplan–Meier estimator using log-rank testing. To address later adoption of EUS-BD, we also estimated a restricted mean survival time of 180 days (RMST_0–180) with 95% confidence intervals (CIs). Results: Baseline inflammatory markers and composite indices were similar; baseline total bilirubin was higher in PTBD. The technical success was 100% in both groups. Early biochemical response was 86.5% after EUS-BD vs. 78.1% after PTBD (p = 0.43). Any complication occurred in 29.7% vs. 12.5% (p = 0.04); major complications (Clavien–Dindo ≥ III) occurred in 10.8% vs. 0% (p = 0.02), respectively; and the LOS did not differ (p = 0.21). OS favored EUS-BD (median 143 vs. 54 days and log-rank p = 0.012). RMST_0–180 was 111.1 days for EUS-BD vs. 71.4 days for PTBD (difference + 39.6 days; 95% CI 11.3–65.9). Conclusions: After a failed ERCP for MBO, EUS-BD and PTBD achieved universal technical success and similar early biochemical responses, but EUS-BD was associated with higher complication rates and a significantly longer six-month survival. These findings support the individualized selection balancing procedural risk with the anticipated survival benefit and highlight the need for prospective comparative studies.
- 20 February 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (5) , 1103-1117
Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges
Pancreatic cancer is one of the most thrombogenic malignancies. Venous thromboembolism (VTE) is a frequent and very severe complication. The risk of thrombosis and postoperative hemorrhage, especially post-pancreatectomy, makes thromboprophylaxis difficult to implement in clinical practice depending on what component dominates. A review was conducted using PubMed, Scopus, Web of Science, Elsevier, and Google Scholar databases. Studies published in English focusing on VTE pathophysiology, prevention, and treatment in pancreatic cancer were included. The evidence was summarized descriptively. Two randomized trials (FRAGEM and CONKO-004) have shown that intensified, weight-adjusted low–molecular-weight heparin (LMWH) significantly decreases the incidence of VTE in advanced pancreatic cancer (PC) without significantly increasing major bleeding or enhancing survival rates. Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban present potential as oral alternatives; however, they are associated with a greater risk of gastrointestinal bleeding. Following pancreatectomy, VTE occurs in 20–25% of patients—frequently after discharge—highlighting the necessity for extended prophylaxis lasting at least 28 days. Minimally invasive surgical techniques are linked to a marginally elevated risk of VTE when compared to open surgery. Nevertheless, the available data concerning dosing, timing, and the resumption of anticoagulation after post-pancreatectomy hemorrhage (PPH) is still inadequate. Current evidence supports the use of LMWH-based anticoagulation strategies for VTE prevention in pancreatic cancer; however, direct evidence for standard prophylactic dosing is lacking, as available randomized trials evaluated intensified regimens. DOACs may be used selectively, considering bleeding risk. The lack of pancreatic-cancer-specific dosing protocols and perioperative guidelines highlights the need for dedicated trials defining optimal anticoagulation strategies and safe timing of therapy after PPH.
- 20 February 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (5) , 1103-1117
Coagulation disorders and thromboprophylaxis in pancreatic cancer: a review of current evidence and clinical challenges
Pancreatic cancer is one of the most thrombogenic malignancies. Venous thromboembolism (VTE) is a frequent and very severe complication. The risk of thrombosis and postoperative hemorrhage, especially post-pancreatectomy, makes thromboprophylaxis difficult to implement in clinical practice depending on what component dominates. A review was conducted using PubMed, Scopus, Web of Science, Elsevier, and Google Scholar databases. Studies published in English focusing on VTE pathophysiology, prevention, and treatment in pancreatic cancer were included. The evidence was summarized descriptively. Two randomized trials (FRAGEM and CONKO-004) have shown that intensified, weight-adjusted low–molecular-weight heparin (LMWH) significantly decreases the incidence of VTE in advanced pancreatic cancer (PC) without significantly increasing major bleeding or enhancing survival rates. Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban present potential as oral alternatives; however, they are associated with a greater risk of gastrointestinal bleeding. Following pancreatectomy, VTE occurs in 20–25% of patients—frequently after discharge—highlighting the necessity for extended prophylaxis lasting at least 28 days. Minimally invasive surgical techniques are linked to a marginally elevated risk of VTE when compared to open surgery. Nevertheless, the available data concerning dosing, timing, and the resumption of anticoagulation after post-pancreatectomy hemorrhage (PPH) is still inadequate. Current evidence supports the use of LMWH-based anticoagulation strategies for VTE prevention in pancreatic cancer; however, direct evidence for standard prophylactic dosing is lacking, as available randomized trials evaluated intensified regimens. DOACs may be used selectively, considering bleeding risk. The lack of pancreatic-cancer-specific dosing protocols and perioperative guidelines highlights the need for dedicated trials defining optimal anticoagulation strategies and safe timing of therapy after PPH.
- Open Access
- 3 February 2026
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 42 (1) , 93-99
Preliminary single-operator experience with ultrasound-guided liver core needle biopsy performed by a supervised general surgery resident
Preliminary single-operator experience with ultrasound-guided liver core needle biopsy performed by a supervised general surgery resident - Turkish Journal of Surgery
- 3 February 2026
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 42 (1) , 93-99
Open AccessPreliminary single-operator experience with ultrasound-guided liver core needle biopsy performed by a supervised general surgery resident
Preliminary single-operator experience with ultrasound-guided liver core needle biopsy performed by a supervised general surgery resident - Turkish Journal of Surgery
- Open Access
- 8 January 2026
- Published by MDPI AG in Surgical Techniques Development
- Vol. 15 (1) , 4
Radiofrequency Ablation (RFA) with Biliary Stenting in Malignant Biliary Obstruction: Case Series from a Single-Institution
Background/Objectives: Endoscopic biliary stenting is the standard palliative intervention for malignant biliary obstruction, aimed at restoring ductal patency. Radiofrequency ablation (RFA) has been introduced as an adjunct technique to improve stent durability and patient outcomes. However, the literature remains inconclusive regarding which patients are most likely to benefit from the combination of RFA and stenting. Methods: We retrospectively described clinical outcomes of 24 patients undergoing endobiliary RFA combined with biliary stenting for malignant biliary obstruction. Post-procedural and 6-month outcomes were assessed using technical success and changes in serum bilirubin; procedure-related adverse events were extracted from available medical records. Results: Nineteen females and five males were included in the study. The most prevalent diagnoses were metastatic adenocarcinoma (n = 8) and cholangiocarcinoma (n = 6). 25% of patients did not complete the 6-month follow-up due to malignancy progression. 16 out of 18 maintained the patency of biliary stents. Repeat endoscopic intervention for suspected stent dysfunction was documented in one patient. When analyzed in an intention-to-treat manner (counting deaths before 6 months as failures), the corresponding 6-month patency/clinical success rate was 16/24 (66.7%). Conclusions: In this retrospective single-center experience, RFA combined with biliary stenting was feasible and was associated with maintained biliary drainage in a majority of patients who survived to the 6-month assessment.
- 8 January 2026
- Published by MDPI AG in Surgical Techniques Development
- Vol. 15 (1) , 4
Open AccessRadiofrequency Ablation (RFA) with Biliary Stenting in Malignant Biliary Obstruction: Case Series from a Single-Institution
Background/Objectives: Endoscopic biliary stenting is the standard palliative intervention for malignant biliary obstruction, aimed at restoring ductal patency. Radiofrequency ablation (RFA) has been introduced as an adjunct technique to improve stent durability and patient outcomes. However, the literature remains inconclusive regarding which patients are most likely to benefit from the combination of RFA and stenting. Methods: We retrospectively described clinical outcomes of 24 patients undergoing endobiliary RFA combined with biliary stenting for malignant biliary obstruction. Post-procedural and 6-month outcomes were assessed using technical success and changes in serum bilirubin; procedure-related adverse events were extracted from available medical records. Results: Nineteen females and five males were included in the study. The most prevalent diagnoses were metastatic adenocarcinoma (n = 8) and cholangiocarcinoma (n = 6). 25% of patients did not complete the 6-month follow-up due to malignancy progression. 16 out of 18 maintained the patency of biliary stents. Repeat endoscopic intervention for suspected stent dysfunction was documented in one patient. When analyzed in an intention-to-treat manner (counting deaths before 6 months as failures), the corresponding 6-month patency/clinical success rate was 16/24 (66.7%). Conclusions: In this retrospective single-center experience, RFA combined with biliary stenting was feasible and was associated with maintained biliary drainage in a majority of patients who survived to the 6-month assessment.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Formosan Journal of Surgery
- Vol. 59 (1) , 43-44
A minimally invasive alternative to pancreatoduodenectomy: Piecemeal endoscopic mucosal resection in the treatment of duodenal tumors—Benefits and the risk of serious complications
An abstract is unavailable. This article is available as a PDF only.
- 1 January 2026
- Published by Wolters Kluwer Health in Formosan Journal of Surgery
- Vol. 59 (1) , 43-44
Open AccessA minimally invasive alternative to pancreatoduodenectomy: Piecemeal endoscopic mucosal resection in the treatment of duodenal tumors—Benefits and the risk of serious complications
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 26 November 2025
- Published by MDPI AG in Preprints.org
Radiofrequency Ablation (RFA) with Biliary Stenting in Malignant Biliary Obstruction: Single-Institution Experience
Background/Objectives: Endoscopic biliary stenting is the standard palliative intervention for malignant biliary obstruction, aimed at restoring ductal patency. Radiofrequency ablation (RFA) has been introduced as an adjunct technique to improve stent durability and patient outcomes. However, the literature remains inconclusive regarding which patients are most likely to benefit from the combination of RFA and stenting. Methods: To assess clinical outcomes of patients undergoing RFA with biliary stenting and identify the factors associated with treatment success, clinical data were collected from 24 patients suffering from non-resectable malignancies. Post-procedural and 6-month follow-up clinical success and complication rates were measured by the technical success of RFA and a decrease in blood bilirubin levels. Results: Nineteen females and five males were included in the study. The most prevalent diagnoses were metastatic adenocarcinoma (n = 8) and cholangiocarcinoma (n = 6). 25% of patients did not complete the 6-month follow-up due to malignancy progression. 16 out of 18 maintained the patency of biliary stents and were able to continue the oncological treatment. The two patients required multiple unsuccessful endoscopic interventions. Conclusions: RFA with biliary stenting is a very effective, safe method for maintaining biliary patency in cases of unresectable biliary malignant obstruction. While we did not identify any specific factors associated with treatment success or failure, our findings support the use of RFA with biliary stenting as a safe, feasible option in non-resectable malignancies of the biliary tract.
- 26 November 2025
- Published by MDPI AG in Preprints.org
Open AccessRadiofrequency Ablation (RFA) with Biliary Stenting in Malignant Biliary Obstruction: Single-Institution Experience
Background/Objectives: Endoscopic biliary stenting is the standard palliative intervention for malignant biliary obstruction, aimed at restoring ductal patency. Radiofrequency ablation (RFA) has been introduced as an adjunct technique to improve stent durability and patient outcomes. However, the literature remains inconclusive regarding which patients are most likely to benefit from the combination of RFA and stenting. Methods: To assess clinical outcomes of patients undergoing RFA with biliary stenting and identify the factors associated with treatment success, clinical data were collected from 24 patients suffering from non-resectable malignancies. Post-procedural and 6-month follow-up clinical success and complication rates were measured by the technical success of RFA and a decrease in blood bilirubin levels. Results: Nineteen females and five males were included in the study. The most prevalent diagnoses were metastatic adenocarcinoma (n = 8) and cholangiocarcinoma (n = 6). 25% of patients did not complete the 6-month follow-up due to malignancy progression. 16 out of 18 maintained the patency of biliary stents and were able to continue the oncological treatment. The two patients required multiple unsuccessful endoscopic interventions. Conclusions: RFA with biliary stenting is a very effective, safe method for maintaining biliary patency in cases of unresectable biliary malignant obstruction. While we did not identify any specific factors associated with treatment success or failure, our findings support the use of RFA with biliary stenting as a safe, feasible option in non-resectable malignancies of the biliary tract.
- 23 October 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 36 (2) , 320-327
Long-Term Body Mass Index Changes Following Kidney Transplantation: Predictors Over a 10-Year Follow-Up
- 23 October 2025
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 36 (2) , 320-327
Long-Term Body Mass Index Changes Following Kidney Transplantation: Predictors Over a 10-Year Follow-Up
- 23 July 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (5) , 19-24
The usefulness of magnetic resonance imaging in the assessment of pancreaticojejunostomy after modified Puestow procedure – a single-centre study
Introduction: Lateral pancreaticojejunostomy (LPJ) remains the most commonly performed decompressive procedure for symptomatic patients with chronic pancreatitis (CP) and a dilated pancreatic duct (PD) who failed at either conservative or endoscopic treatment. An accurate interpretation of the long-term appearance of LPJ is mostly unknown.Aim: The aim of our study was to determine the utility of the longitudinal magnetic resonance imaging (MRI) in the long-termevaluation of the aforementioned anastomoses postoperatively.Materials and methods: The study was conducted among patients admitted to the Department of General and Transplant Surgery after LPJ between 2009 and 2018. Magnetic resonance imaging scans were performed in accordance with the routine schedule of follow-up.Results: The study group consisted of 25 patients (14 males) who underwent LPJ due to CP with dilatation of PD (mean 7.5mm [SD 3.69]) without calculi. Seven of them had the imaging examination performed within a one-year follow-up; the other18 patients were up to 10 years after surgery. The patency of the anastomosis was directly observed in 10 patients, in 11 patientsit was established on the basis of indirect features, and in the rest the first diagnosis was uncertain and required radiologicalreanalysis, during which the patency of all anastomoses was confirmed.Conclusions: MRI is an effective diagnostic tool that can be successfully used in a follow-up process after LPJ, as it allows to show the presence of pancreaticojejunal anastomosis. However, more studies regarding this subject should be conducted as we lack high-volume data.
- 23 July 2025
- Published by Index Copernicus in Polish Journal of Surgery
- Vol. 97 (5) , 19-24
The usefulness of magnetic resonance imaging in the assessment of pancreaticojejunostomy after modified Puestow procedure – a single-centre study
Introduction: Lateral pancreaticojejunostomy (LPJ) remains the most commonly performed decompressive procedure for symptomatic patients with chronic pancreatitis (CP) and a dilated pancreatic duct (PD) who failed at either conservative or endoscopic treatment. An accurate interpretation of the long-term appearance of LPJ is mostly unknown.Aim: The aim of our study was to determine the utility of the longitudinal magnetic resonance imaging (MRI) in the long-termevaluation of the aforementioned anastomoses postoperatively.Materials and methods: The study was conducted among patients admitted to the Department of General and Transplant Surgery after LPJ between 2009 and 2018. Magnetic resonance imaging scans were performed in accordance with the routine schedule of follow-up.Results: The study group consisted of 25 patients (14 males) who underwent LPJ due to CP with dilatation of PD (mean 7.5mm [SD 3.69]) without calculi. Seven of them had the imaging examination performed within a one-year follow-up; the other18 patients were up to 10 years after surgery. The patency of the anastomosis was directly observed in 10 patients, in 11 patientsit was established on the basis of indirect features, and in the rest the first diagnosis was uncertain and required radiologicalreanalysis, during which the patency of all anastomoses was confirmed.Conclusions: MRI is an effective diagnostic tool that can be successfully used in a follow-up process after LPJ, as it allows to show the presence of pancreaticojejunal anastomosis. However, more studies regarding this subject should be conducted as we lack high-volume data.